ChromaDex (ChromaDex) FCF Margin % : 2.96% (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is ChromaDex FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ChromaDex's Free Cash Flow for the three months ended in Dec. 2023 was $0.63 Mil. ChromaDex's Revenue for the three months ended in Dec. 2023 was $21.20 Mil. Therefore, ChromaDex's FCF Margin % for the quarter that ended in Dec. 2023 was 2.96%.

As of today, ChromaDex's current FCF Yield % is 2.58%.

The historical rank and industry rank for ChromaDex's FCF Margin % or its related term are showing as below:

CDXC' s FCF Margin % Range Over the Past 10 Years
Min: -70.86 Med: -21.47 Max: 8.34
Current: 8.34

During the past 13 years, the highest FCF Margin % of ChromaDex was 8.34%. The lowest was -70.86%. And the median was -21.47%.

CDXC's FCF Margin % is ranked better than
85.48% of 1033 companies
in the Biotechnology industry
Industry Median: -148.24 vs CDXC: 8.34

ChromaDex FCF Margin % Historical Data

The historical data trend for ChromaDex's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChromaDex FCF Margin % Chart

ChromaDex Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-45.78

-18.13

-36.43

-21.42

8.34

ChromaDex Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-2.38	11.97	16.09	1.90	2.96

Competitive Comparison of ChromaDex's FCF Margin %

For the Biotechnology subindustry, ChromaDex's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ChromaDex's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ChromaDex's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ChromaDex's FCF Margin % falls into.

ChromaDex FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ChromaDex's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	6.969	/	83.57
	=	8.34 %

ChromaDex's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0.628	/	21.196
	=	2.96 %

ChromaDex FCF Margin % Related Terms

Thank you for viewing the detailed overview of ChromaDex's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ChromaDex (ChromaDex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChromaDex Corp (NAS:CDXC) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

OCD1:Germany

Address

10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024

Website

https://www.chromadex.com

ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segment namely Consumer Products, Ingredients segment and Analytical Reference Standards and Services. Majority of the revenue is earned from Consumer Products segment.

Executives

Brianna Gerber	officer: SVP Finance / Interim CFO	C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Champion River Ventures Ltd	10 percent owner	C/O 7F, CHEUNG KONG CENTER, 2 QUEEN'S ROAD, CENTRAL K3 00000
Jaksch Frank L Jr	director, 10 percent owner, officer: Chief Executive Officer	10005 MUIRLANDS BOULEVARD, SUITE G FIRST FLOOR, IRVINE CA 92618
Robert N Fried	director	100 NORTH CRESCENT DRIVE, BEVERLY HILLS CA 90210
Steven D Rubin	director	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Li Ka Shing	10 percent owner	79 DEEP WATER BAY ROAD, HONG KONG F4 00000
Chau Hoi Shuen Solina Holly	10 percent owner	SUITES PT. 2909 & 2910, HARBOUR CENTRE, 25 HARBOUR ROAD, WANCHAI K3 999077
Hamed Shahbazi	director	C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Ann Cohen	director	C/O CHROMADEX CORPORATION, 10900 WILSHIRE BLVD. STE 600, LOS ANGELES CA 90024
Kristin Patrick	director	3329 CAY DRIVE, SHERMAN OAKS CA 91423
Ng Wang Yu Gary	director	ROOM 1709 HARBOUR CENTER, 25 HARBOUR ROAD, WANCHAI K3 -
Caroline S Levy	director	2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
Stephen A Block	director	INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 WEST 57TH ST, NEW YORK NY 10019
Lisa Hatton Harrington	officer: General Counsel	53 SEA TERRACE, NEWPORT COAST CA 92657
Kevin M Farr	officer: Chief Financial Officer	MATTEL, INC., 333 CONTINENTAL BLVD, M1-1518, EL SEGUNDO CA 90245